Aug 13, 2026 08:30AM

Dec 11, 2025 02:23AM

Dec 2, 2025 07:00AM

Dec 2, 2025 07:00AM

Aug 8, 2025 07:51AM

Mar 24, 2025 04:55AM

Sep 30, 2024 07:27AM H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

Sep 26, 2024 08:01AM

Sep 26, 2024 08:00AM

Aug 13, 2024 08:00AM

Aug 6, 2024 04:01PM

Jul 23, 2024 08:00AM

Jul 10, 2024 08:08AM

Jul 10, 2024 08:00AM eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Jul 1, 2024 08:02AM

Jul 1, 2024 08:00AM

Jun 18, 2024 04:51AM

Mar 8, 2024 08:00AM

Nov 8, 2022 08:00AM

Nov 8, 2022 08:00AM

Jun 6, 2022 08:00AM Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

May 26, 2021 08:19AM

May 26, 2021 08:00AM

Apr 20, 2021 08:00AM

Mar 15, 2021 08:00AM

Mar 3, 2021 09:28AM

Dec 2, 2020 09:28AM

Dec 1, 2020 04:53PM Ovid Therapeutics (OVID) Phase 3 NEPTUNE Clinical Trial of OV101 for Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

Dec 1, 2020 04:52PM

Nov 23, 2020 04:01PM

Nov 12, 2020 04:10PM

Oct 14, 2020 07:00AM

Oct 12, 2020 07:00AM

Sep 30, 2020 08:05AM

Sep 30, 2020 08:00AM Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies

Aug 25, 2020 09:30AM

Aug 10, 2020 08:00AM

Jul 23, 2020 07:00AM

Jul 13, 2020 09:00AM

Jul 13, 2020 07:02AM

Jul 13, 2020 07:00AM

Jun 19, 2020 08:03AM Ovid Therapeutics (OVID) Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome

Jun 19, 2020 08:00AM

May 7, 2020 07:48AM

May 7, 2020 07:30AM

Mar 30, 2020 08:00AM

Mar 11, 2020 08:00AM

Jan 7, 2020 08:03AM

Jan 7, 2020 08:00AM Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform

Sep 23, 2019 07:07AM

328,513 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All